Alzamend Neuro (ALZN) Income from Continuing Operations (2020 - 2026)

Alzamend Neuro has disclosed Income from Continuing Operations across 7 years of filings, most recently posting -$2.9 million for Q2 2026.

• In Q2 2026, Income from Continuing Operations fell 151.97% year-over-year to -$2.9 million; the TTM figure through Apr 2026 stood at -$8.8 million (down 94.32% YoY), while the FY2026 annual figure was -$8.8 million, down 94.3% from the prior year.
• Income from Continuing Operations came in at -$2.9 million for Q2 2026 at Alzamend Neuro, down from -$2.2 million in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of -$851529.0 in Q2 2024 to a low of -$5.4 million in Q1 2023.
• Average Income from Continuing Operations over 5 years is -$2.5 million, with a median of -$2.7 million recorded in 2024.
• Year-over-year, Income from Continuing Operations plunged 208.83% in 2022 and soared 74.24% in 2024.
• Over 5 years, Income from Continuing Operations stood at -$3.1 million in 2022, then rose by 6.56% to -$2.9 million in 2023, then soared by 53.15% to -$1.4 million in 2024, then gained by 26.5% to -$1.0 million in 2025, then plunged by 186.89% to -$2.9 million in 2026.
• Per Business Quant data, the three most recent Income from Continuing Operations figures were -$2.9 million in Q2 2026, -$2.2 million in Q1 2026, and -$1.0 million in Q4 2025.